EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pharmacological Management of Oral and Esophageal Candidiasis: A Clinical Pharmacotherapy Perspective

Toshinori Hirai iD, Masanori Nashi iD

Journal of Clinical Medicine · 24.10.2025 · 14 (21) · 7537

DOI: 10.3390/jcm14217537 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 24.10.2025. Verfasst von Toshinori Hirai und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Institute of Science Tokyo Hospital, 1-5-45 Yushima, Bunkyo-ku 113-8519, Tokyo, Japan. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 187 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Candida spp. are common components of normal microbiota in the oral cavity. However, Candida albicans can be a primary cause of superficial infections in the oral cavity and esophagus, especially in immunocompromised individuals. While these infections are rarely life-threatening, they can significantly impair quality of life and, in severe cases, progress to hematogenous dissemination. Oral candidiasis often exhibits as pseudomembranous, erythematous (atrophic), chronic hyperplastic, denture stomatitis, or angular cheilitis. Esophageal candidiasis is typically diagnosed by upper endoscopy, which involves histological examination and brushing. Clinical guidelines recommend topical antifungal agents for mild oral candidiasis, and systemic agents for moderate-to-severe disease or when topical therapy fails. However, azole antifungals pose a substantial risk of drug–drug interactions, primarily due to the inhibition of cytochrome P450 enzymes and drug transporters, which dramatically alters the pharmacokinetics of co-administered drugs. Additionally, amphotericin B, a polyene macrolide antibiotic, may cause nephrotoxicity and electrolyte disturbances (e.g., hypokalemia and hypomagnesemia). Moreover, the co-administration of nephrotoxic drugs may augment the toxicity associated with amphotericin B. Therefore, this review aimed to provide a comprehensive overview of the management of oral and esophageal candidiasis from the viewpoint of clinical pharmacology, with a particular focus on drug–drug interactions and adverse effect profiles.

Schlagwörter

Stichwörter der Autor:innen

Candidaantifungalsdrug–drug interactionspharmacotherapytoxicity

Autor:innen und Institutionen

  • Department of Pharmacy, Institute of Science Tokyo Hospital, 1-5-45 Yushima, Bunkyo-ku 113-8519, Tokyo, Japan.
  • Department of Oral and Maxillofacial Surgery, Nishinomiya Watanabe Hospital, 10-22 Murokawa-cho, Nishinomiya 662-0863, Hyogo, Japan.

ORCID-Profile: Toshinori Hirai, Masanori Nashi

Zitieren

APA

Hirai, T., & Nashi, M. (2025). Pharmacological Management of Oral and Esophageal Candidiasis: A Clinical Pharmacotherapy Perspective. Journal of Clinical Medicine, 14(21), 7537. https://doi.org/10.3390/jcm14217537

Vancouver

Hirai T, Nashi M. Pharmacological Management of Oral and Esophageal Candidiasis: A Clinical Pharmacotherapy Perspective. Journal of Clinical Medicine. 2025;14(21):7537. doi:10.3390/jcm14217537

BibTeX
@article{Hirai2025,
  author = {Hirai, Toshinori and Nashi, Masanori},
  title = {Pharmacological Management of Oral and Esophageal Candidiasis: A Clinical Pharmacotherapy Perspective},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {21},
  pages = {7537},
  doi = {10.3390/jcm14217537}
}
Kostenlos starten →